A non‐cytotoxic regimen of decitabine to treat refractory T‐cell large granular lymphocytic leukemia
Abstract We report on a novel, successful, non‐cytotoxic therapy to treat multiply‐refractory T‐LGL in an elderly patient.
Main Authors: | Misam Zawit, Carmelo Gurnari, Simona Pagliuca, Hassan Awada, Jaroslaw P. Maciejewski, Yogen Saunthararajah |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-09-01
|
Series: | Clinical Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/ccr3.4533 |
Similar Items
-
Large Granular Lymphocytic Leukemia: From Immunopathogenesis to Treatment of Refractory Disease
by: Misam Zawit, et al.
Published: (2021-09-01) -
Patients with AML-MRC benefit from decitabine in combination with low-dose G-CSF, cytarabine and aclarubicin: A single center cohort study
by: Jing Liu, et al.
Published: (2022-01-01) -
Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure
by: Junxia Hu, et al.
Published: (2021-06-01) -
Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma
by: Xiaoshuang Kong, et al.
Published: (2023-04-01) -
A Retrospective Observation of Treatment Outcomes Using Decitabine-Combined Standard Conditioning Regimens Before Transplantation in Patients With Relapsed or Refractory Acute Myeloid Leukemia
by: Yuhang Li, et al.
Published: (2021-08-01)